Vascular Pharmaceuticals, PhytoChem Pharmaceuticals To Participate at CED's December STREAK Seminar
Dec. 10 Seminar Offers Professional Mentoring For Life Science Startups
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Dec 10, 2009 - CED, formerly the Council for Entrepreneurial Development (www.cednc.org), a private, nonprofit organization that promotes entrepreneurial efforts in the Triangle region of North Carolina, has announced that it will host the next installment of its popular STREAK program, to be held Thursday, Dec. 10 from 3 p.m. to 5 p.m. STREAK is designed to assist early-stage, high-growth life sciences and technology companies in preparing for and reaching fundraising goals through the critique of pitch presentations by a seasoned panel of investors, entrepreneurs and marketing experts.
Presenters at the seminar include Richard Shea, CEO of Vascular Pharmaceuticals and Timothy Klapish, COO of PhytoChem Pharmaceuticals (www.phytochem.com). Panelists include Phillipa Charlton, M.D. MPH, medical director at Tranzyme Pharma; Clayton Duncan, president and CEO of Vindica Therapeutics; Christopher Humprey, partner at Alston & Bird LLP; Charles Osborne, CFO at Scynexis Inc.; Tom Roberg, CEO and executive chairman at LAAM Sciences Inc.; Scott Weiner, principal at Pappas Ventures; and William Wofford, partner at Hutchison Law Group.
STREAK is a closed-door session opportunity that is only available to CED members and takes place on the second Thursday afternoon of each month. Of the 12 companies selected to present before the panels, CED will select the most notable presenters to showcase at a January event. For details on entry criteria and the application process, CED members should e-mail their business plan and other relevant information to program coordinators Bob Pickens at email@example.com or Dhruv Patel at firstname.lastname@example.org.
“We are excited to have PhytoChem and Vascular Pharmaceuticals, two cutting-edge pharmaceutical companies, present at our December STREAK seminar,” said Bob Pickens, director of entrepreneurship at CED. “The STREAK program will allow them the chance to take their companies to the next stage and add to their future success.”
NEW MEDIA CONTENT:
CED Twitter page
- Vascular Pharmaceuticals is focused on the development and commercialization of novel therapeutic products for the treatment of cardiovascular and metabolic complications related to diabetes.
- The major focus of the Vascular Pharmaceuticals is advancing the lead program in diabetic atherosclerosis into human clinical trials in late 2011.
- PhytoChem Pharmaceuticals is a growing pharmaceutical firm focused on research of natural compounds targeted at cardiovascular, cancer, and dermatological conditions.
- One of CED's most popular and valuable offerings, STREAK provides members the opportunity to submit their business plan and investor pitch for consideration to present before a custom-built expert panel. The panelists are hand-picked to address the specific needs of each company by providing feedback on strategy, business advice, funding options and additional relevant contacts. STREAK is sponsored by Hutchison Law Group and Hughes Pittman & Gupton, LLP.
CED (formerly The Council for Entrepreneurial Development) is a private, nonprofit organization founded in 1984 to identify, enable and promote high-growth, high-impact companies and accelerate the region's entrepreneurial culture. Headquartered in the Research Triangle Park, CED is the oldest and largest entrepreneurial support organization in the nation with more than 5,500 active members. CED provides know-how, networking, mentoring and capital formation resources to new and existing high-growth entrepreneurs through annual conferences, programs and web-based resources. CED has helped entrepreneurs, investors, service partners, researchers and public policy makers in diverse emerging industries and at all stages of development – from high-tech, production-based organizations to service companies, from one-person start-ups to 1000-person businesses. Visit www.cednc.org for more information.
Posted: December 2009